JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that …
JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single …
JEMPERLI, in combination with carboplatin and paclitaxel, for dMMR or MSI-H primary advanced or recurrent endometrial cancer: 500 mg every 3 weeks for 6 doses followed by 1,000 mg …
JEMPERLI Dosing and Administration Guide Indications Endometrial Cancer • JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is …
The recommended dosage of JEMPERLI is: • Dose 1 through Dose 4: 500 mg every 3 weeks • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every 6 …
Jemperli (GlaxoSmithKline LLC): FDA Package Insert
Aug 1, 2024 · JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or …
JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced: • endometrial cancer (EC), as determined by an FDA-approved test, …
Jemperli is for intravenous infusion after dilution (see 4.3 Reconstitution; 4.4 Administration). Patients should be selected for treatment based on MSI-H or dMMR tumour status as …
JEMPERLI (dostarlimab for injection) is indicated as: monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) …
JEMPERLI, in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent …
- Some results have been removed